The long-term goal of the Lymphoid Development and Malignancy (LDM) Program is to improve outcomes and seek cures for patients with lymphoid malignancies, including acute lymphoblastic leukemia (ALL) and B cell non-Hodgkin lymphoma (B-NHL). The Program is motivated by the notion that new therapeutic modalities of high efficacy and low toxicity can be developed by specifically targeting the altered oncogenic pathways of malignant cells. To achieve this end, the following Specific Goals will be pursued: 1. Identify major cellular pathways that regulate the development of lymphoid tissues. Molecular .biology, genetic and systems biology approaches will be used to elucidate cellular pathways that regulate the growth, survival and differentiation of immature lymphocytes (the precursors of ALL) and mature B cells (the precursors of B-NHL). 2. Identify genes and pathways involved in the pathogenesis of lymphoid malignancies. In particular, the genetic lesions and deregulated cellular pathways that are casually associated with the pathogenesis of ALL and B-NHL will be identified. 3. Develop novel therapies that target the deregulated cellular pathways of lymphoid malignancies. Known drugs as well as compounds identified through screening approaches will be tested as single agents and in combinations for their ability to target deregulated pathways in lymphoid malignancies using pre-clinical models and Phase I/I I clinical trials. The LDM Program consists of 28 members (17 full members, 5 clinical members, and 6 associate members) from 10 departments within the College of Physicians &Surgeons at Columbia University, as well as 4 members from the Weill Cornell Medical Center. The Program is supported by large program project grants, including a Leukemia Lymphoma Society Specialized Center of Research (SCOR) grant on "Molecular Targets in Lymphoma" and a grant from the National Center for multi-scale study of Cellular Networks. For the last budget year of the grant (July 1, 2006 - June 30, 2007), the LDM Program received a total of $10.4M (direct costs) in cancer-relevant grant support, including $3.6M (direct costs) in NCI funding, $4.3M (direct costs) in other cancer-related peer-reviewed funding, and $2.5M (direct costs) in cancer-related non-peer-reviewed funding. The total number of cancer-related publications since the previous submission (i.e., 2003-present) was 202, of which 12.9% were intra-programmatic and 10.4% inter-programmatic.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
New York
United States
Zip Code
Bassuk, Alexander G; Sujirakul, Tharikarn; Tsang, Stephen H et al. (2014) A novel RPGR mutation masquerading as Stargardt disease. Br J Ophthalmol 98:709-11
Li, Yao; Wu, Wen-Hsuan; Hsu, Chun-Wei et al. (2014) Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects. Mol Ther 22:1688-97
Wert, Katherine J; Sancho-Pelluz, Javier; Tsang, Stephen H (2014) Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet 23:514-23
Shen, Sherry; Sujirakul, Tharikarn; Tsang, Stephen H (2014) Next-generation sequencing revealed a novel mutation in the gene encoding the beta subunit of rod phosphodiesterase. Ophthalmic Genet 35:142-50
Palomero, Teresa; Couronné, Lucile; Khiabanian, Hossein et al. (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166-70
Higuchi-Sanabria, Ryo; Pernice, Wolfgang M A; Vevea, Jason D et al. (2014) Role of asymmetric cell division in lifespan control in Saccharomyces cerevisiae. FEMS Yeast Res 14:1133-46
Lam, A T; Curschellas, C; Krovvidi, D et al. (2014) Controlling self-assembly of microtubule spools via kinesin motor density. Soft Matter 10:8731-6
Olszak, Torsten; Neves, Joana F; Dowds, C Marie et al. (2014) Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 509:497-502
Murtomaki, Aino; Uh, Minji K; Kitajewski, Chris et al. (2014) Notch signaling functions in lymphatic valve formation. Development 141:2446-51
Nong, Eva; Lee, Winston; Merriam, Joanna E et al. (2014) Disease progression in autosomal dominant cone-rod dystrophy caused by a novel mutation (D100G) in the GUCA1A gene. Doc Ophthalmol 128:59-67

Showing the most recent 10 out of 142 publications